(RTTNews) - iBio, Inc. (IBIO) Monday reported encouraging data from a non-GLP non-human primate (NHP) pharmacokinetics study of the company's lead drug candidate IBIO-600 for the treatment of obesity. The study was designed to evaluate the potential of IBIO-600 in NHPs by determining the antibody's half-life in serum and analyzing changes in lean and fat mass. Data from the study suggests that IBIO-600 could have a human half-life as long as 130 days. Further, IBIO-600 promoted a dose-dependent increase in lean mass and a reduction in fat mass from baseline values.
iBio is on track for a regulatory submission for IBIO-600 in the first quarter of 2026.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
